Literature DB >> 31670405

Parthanatos-associated proteins are stimulated intraocularly during development of experimental murine cytomegalovirus retinitis in mice with retrovirus-induced immunosuppression.

Jay J Oh1, Jessica J Carter1,2, Judee Grace E Nemeno1, Richard D Dix1,2.   

Abstract

The mechanisms that contribute to retinal tissue destruction during the onset and progression of AIDS-related human cytomegalovirus (HCMV) retinitis remain unclear. Evidence for the stimulation of multiple cell death pathways including apoptosis, necroptosis, and pyroptosis during the pathogenesis of experimental murine cytomegalovirus (MCMV) retinitis in mice with retrovirus-induced immunosuppression (MAIDS) has been reported. Parthanatos is a caspase-independent cell death pathway mediated by rapid overactivation of poly (ADP-ribose) polymerase-1 (PARP-1) and distinct from other cell death pathways. Using the MAIDS model of MCMV retinitis, studies were performed to test the hypothesis that intraocular MCMV infection of mice with MAIDS stimulates parthanatos-associated messenger RNAs (mRNAs) and proteins within the eye during the development of retinal necrosis that takes place by 10 days after MCMV infection. MCMV-infected eyes of MAIDS mice exhibited significant stimulation of PARP-1 mRNA and proteins at 3 days after infection but declined thereafter at 6 and 10 days after infection. Additional studies showed the intraocular stimulation of mRNAs or proteins before MCMV retinitis development for two additional participants in parthanatos, polymer of ADP-ribose and poly (ADP-ribose) glycohydrolase. These results provide new evidence for a role for parthanatos during MAIDS-related MCMV retinitis that may also extend to AIDS-related HCMV retinitis.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  AIDS; MAIDS; human cytomegalovirus; murine cytomegalovirus; parthanatos; retinitis

Mesh:

Substances:

Year:  2019        PMID: 31670405      PMCID: PMC8211416          DOI: 10.1002/jmv.25619

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  20 in total

1.  Poly(ADP-ribose) (PAR) polymer is a death signal.

Authors:  Shaida A Andrabi; No Soo Kim; Seong-Woon Yu; Hongmin Wang; David W Koh; Masayuki Sasaki; Judith A Klaus; Takashi Otsuka; Zhizheng Zhang; Raymond C Koehler; Patricia D Hurn; Guy G Poirier; Valina L Dawson; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

2.  TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation.

Authors:  S Jouan-Lanhouet; M I Arshad; C Piquet-Pellorce; C Martin-Chouly; G Le Moigne-Muller; F Van Herreweghe; N Takahashi; O Sergent; D Lagadic-Gossmann; P Vandenabeele; M Samson; M-T Dimanche-Boitrel
Journal:  Cell Death Differ       Date:  2012-07-20       Impact factor: 15.828

3.  Seroprevalence of cytomegalovirus infection in the United States, 1988-1994.

Authors:  Stephanie A S Staras; Sheila C Dollard; Kay W Radford; W Dana Flanders; Robert F Pass; Michael J Cannon
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

4.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Authors:  B Ledergerber; M Egger; V Erard; R Weber; B Hirschel; H Furrer; M Battegay; P Vernazza; E Bernasconi; M Opravil; D Kaufmann; P Sudre; P Francioli; A Telenti
Journal:  JAMA       Date:  1999-12-15       Impact factor: 56.272

5.  Poly(ADP-ribose) glycohydrolase silencing protects against H2O2-induced cell death.

Authors:  Christian Blenn; Felix R Althaus; Maria Malanga
Journal:  Biochem J       Date:  2006-06-15       Impact factor: 3.857

6.  Mice immunosuppressed by murine retrovirus infection (MAIDS) are susceptible to cytomegalovirus retinitis.

Authors:  R D Dix; C Cray; S W Cousins
Journal:  Curr Eye Res       Date:  1994-08       Impact factor: 2.424

Review 7.  Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos.

Authors:  Yingfei Wang; Valina L Dawson; Ted M Dawson
Journal:  Exp Neurol       Date:  2009-03-28       Impact factor: 5.330

8.  HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-β/SMAD signalling pathway.

Authors:  Laura Lucarini; Mariaconcetta Durante; Cecilia Lanzi; Alessandro Pini; Giulia Boccalini; Laura Calosi; Flavio Moroni; Emanuela Masini; Guido Mannaioni
Journal:  J Cell Mol Med       Date:  2016-10-04       Impact factor: 5.310

9.  Reactive oxygen species-induced parthanatos of immunocytes by human cytomegalovirus-associated substance.

Authors:  Jung Heon Kim; Jiyeon Kim; Jin Roh; Chan-Sik Park; Ju-Young Seoh; Eung-Soo Hwang
Journal:  Microbiol Immunol       Date:  2018-03-02       Impact factor: 1.955

10.  Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic.

Authors:  David Heiden; Nathan Ford; David Wilson; William R Rodriguez; Todd Margolis; Bart Janssens; Martha Bedelu; Nini Tun; Eric Goemaere; Peter Saranchuk; Kalpana Sabapathy; Frank Smithuis; Emmanuel Luyirika; W Lawrence Drew
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

View more
  3 in total

Review 1.  Revisiting Regulated Cell Death Responses in Viral Infections.

Authors:  Devasahayam Arokia Balaya Rex; Thottethodi Subrahmanya Keshava Prasad; Richard K Kandasamy
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

2.  Atypical cytomegalovirus retinal disease in pyroptosis-deficient mice with murine acquired immunodeficiency syndrome.

Authors:  Jessica J Carter; Judee Grace E Nemeno; Jay J Oh; John E Houghton; Richard D Dix
Journal:  Exp Eye Res       Date:  2021-06-05       Impact factor: 3.770

3.  Transcriptional analysis of immune response genes during pathogenesis of cytomegalovirus retinitis in mice with murine acquired immunodeficiency syndrome.

Authors:  Jessica J Carter; Jesse M Gardner; Brent P Poling; Madeline M Welch; Judee Grace E Nemeno; John E Houghton; Richard D Dix
Journal:  PLoS Pathog       Date:  2020-11-06       Impact factor: 6.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.